Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 09, 2023 12:28pm

134 Views

Post# 35438745

RE:RE:Conditions are right for biopharma M&A to break out

May 09, 2023 - Takeda confirmed to that the company is making changes “in a few specific areas of the organization that impact some roles as a result.” But the pharma stressed that “there is no plan for a company-wide reduction.” although discovery and preclinical efforts in AAV gene therapy will be discontinued, alongside research and preclinical work in rare hematology. The move was designed to focus resources on core therapeutic areas.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China